Tlhaloso
Li-intermediate tsa rona tsa tofacitinib li bohlokoa ts'ebetsong ea tlhahiso ea tofacitinib, sethethefatsi se tsebahalang se sebelisoang ho alafa mefuta e itseng ea ramatiki.Bohareng bona bo bapala karolo ea bohlokoa tlhahisong ea tofacitinib, e tlatsetsang katlehong le boleng ba eona.Via (2R,3R) -2,3-bis[(4-methylbenzoyl)oxy]succinic acid le (3R,4R)-N,4-dimethyl-1-(phenylmethyl)- Motsoako o nepahetseng oa 3-piperidinamines, rona Sehlahisoa se netefatsa ho kopanngoa ha tofacitinib ea boleng bo holimo e kopanang le ho feta litekanyetso tsa indasteri.
Foromo ea limolek'hule le boima ba tofacitinib ea mahareng ea rona e bonts'a bohloeki le matla a eona, e etsa hore e be karolo e tšepahalang ea ts'ebetso ea tlhahiso ea meriana.Ka metsoako ea eona e lekantsoeng ka hloko, sebaka sena sa mahareng se tiisa botsitso le katleho ea sehlahisoa sa ho qetela, tofacitinib.Mehaho ea eona ea limolek'hule e boetse e kenya letsoho ho tsitsang ka kakaretso ea tofacitinib le bophelo ba sethala, ho netefatsa hore e lula e sebetsa ebile e tšepahala ha nako e telele.
Khetha Rona
JDK e na le lisebelisoa tsa tlhahiso ea maemo a pele le lisebelisoa tsa taolo ea boleng, tse netefatsang phepelo e tsitsitseng ea li-intermediate tsa API.Sehlopha sa litsebi se tiisetsa R&D ka sehlahisoa.Khahlanong le bobeli, re batla CMO & CDMO 'marakeng oa lapeng le oa machabeng.